Drug and Gene Delivery Devices

Global Drug and Gene Delivery Devices Market to Reach US$2.2 Billion by 2030

The global market for Drug and Gene Delivery Devices estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$510.3 Million by the end of the analysis period. Growth in the Inhalation segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$386.1 Million While China is Forecast to Grow at 11.6% CAGR

The Drug and Gene Delivery Devices market in the U.S. is estimated at US$386.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$459.0 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Drug and Gene Delivery Devices Market – Key Trends & Drivers Summarized

How Are Breakthrough Innovations Reshaping Drug and Gene Delivery Devices?
The drug and gene delivery devices market has undergone rapid transformation, driven by cutting-edge innovations in biotechnology, nanomedicine, and advanced material sciences. These devices are no longer just conduits for therapeutic agents but are becoming increasingly sophisticated platforms that enhance specificity, stability, and bioavailability of drugs and genetic material. Techniques like CRISPR-Cas9 and RNA interference (RNAi) have surged in prominence, requiring delivery systems that can precisely target affected cells while minimizing off-target effects. Novel delivery mechanisms such as lipid nanoparticles, viral vectors, and electroporation technologies have emerged to support these precision therapies. Additionally, polymer-based delivery vehicles and microneedle arrays are being actively developed to overcome biological barriers and improve systemic absorption, especially for gene therapies requiring intracellular access. These developments are enabling therapies that were previously not viable due to delivery limitations.

Why Is Personalized Medicine Fueling the Demand for Novel Delivery Platforms?
The transition toward personalized and precision medicine has redefined therapeutic delivery requirements, making the development of customized drug and gene delivery devices essential. Tailoring treatments based on individual genetic profiles demands delivery systems that can adapt to varying molecular weights, solubility characteristics, and tissue targets. As genomic sequencing becomes faster and more accessible, the market is experiencing increased demand for patient-specific therapies, particularly in oncology, rare diseases, and chronic conditions. This has led to a growing need for flexible and modular delivery systems that can be rapidly configured. Furthermore, the rise of combination therapies—blending small molecules with genetic payloads—necessitates dual or multi-modal delivery capabilities. Regulatory agencies are also evolving their frameworks to accommodate the complex nature of personalized therapeutics, which is accelerating approvals and market entry of next-generation delivery devices.

What Role Do Non-Invasive and Targeted Delivery Methods Play in Market Evolution?
Shifting patient preferences and healthcare provider priorities have spurred significant investment in non-invasive and site-specific delivery technologies. Oral, nasal, pulmonary, and transdermal routes are gaining popularity over injectable formats due to better patient compliance and ease of administration. In particular, the inhalable gene therapy segment is gaining momentum, offering a practical alternative for respiratory diseases such as cystic fibrosis and pulmonary hypertension. Smart delivery devices equipped with sensors, microprocessors, and connectivity features are also contributing to this shift, enabling real-time monitoring of therapeutic administration and outcomes. These devices are becoming integral to digital health ecosystems, especially in home-care settings. Moreover, site-specific targeting—achieved through antibody-drug conjugates (ADCs), aptamer systems, and magnetic field-guided nanoparticles—is reducing systemic toxicity and enhancing therapeutic efficacy, paving the way for safer, more efficient treatments.

The Growth in the Drug and Gene Delivery Devices Market Is Driven by Several Factors…
Rapid technological advancements in nano- and micro-scale engineering have revolutionized the design and performance of delivery platforms, enabling controlled release and targeted delivery like never before. The rise in chronic and genetic diseases, alongside increasing clinical trials for gene therapies and nucleic acid-based drugs, is propelling market demand for compatible delivery systems. From an end-use perspective, pharmaceutical companies are investing heavily in next-gen delivery systems to differentiate their biologic portfolios and extend patent life through novel formulations. Academic research institutions and contract research organizations (CROs) are also contributing to pipeline expansion through collaborative development programs. On the consumer side, there is a growing preference for minimally invasive or self-administrable treatment modalities, especially in the aging population and pediatric groups. In parallel, healthcare providers are seeking delivery solutions that integrate with data ecosystems for patient monitoring and treatment optimization. Together, these trends are forging a robust and dynamic market landscape for drug and gene delivery devices globally.

SCOPE OF STUDY:

The report analyzes the Drug and Gene Delivery Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Administration Route (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical); Vector (Viral, Non-viral)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Becton, Dickinson and Company (BD)
• Biogen Inc.
• Bluebird Bio, Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• Halozyme Therapeutics, Inc.
• Johnson & Johnson Services, Inc.
• Kite Pharma, Inc.
• Merck & Co., Inc.
• Moderna, Inc.
• Novartis AG
• Oxford BioMedica plc
• Pfizer Inc.
• Sarepta Therapeutics, Inc.
• Shanghai Sunway Biotech Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.